Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 6% year on year ...
Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting earnings this Thursday afternoon. Here’s what investors should know. McKess...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare providers & services industry, including McKesson ...
In the complex, high-stakes machinery of the American healthcare system, few companies are as indispensable—yet as quietly influential—as McKesson Corporation (NYSE: MCK). As of March 18, 2026, McKesson stands not merely as a distributor of pills and medical supplies, but as a sophisticated healthcare services platform that has successfully pivoted from low-margin logistics to high-value [...]
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
What a fantastic six months it’s been for McKesson. Shares of the company have skyrocketed 42.9%, setting a new 52-week high of $988.29. This performance may have investors wondering how to approach the situation.
The latest data from the U.S. Census Bureau, released in late February 2026, suggests a surprising degree of resilience within the American supply chain. Wholesale inventories for December 2025 rose by a modest 0.2%, reaching a total of $918.0 billion. This figure, which aligns perfectly with analyst
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
McKesson’s fourth-quarter results met Wall Street’s revenue expectations and modestly exceeded consensus for non-GAAP earnings per share, with the market responding positively. Management attributed the growth to robust performance in oncology, expanded biopharma services, and continued momentum in North American pharmaceutical distribution. CEO Brian Tyler specifically highlighted the integration of recent acquisitions such as Florida Cancer Specialists and Prism Vision as meaningful contributors. The company also cited the impact of technology investments, which improved workflow efficiency and productivity across segments.
